Inactive Instrument

Press Releases Actelion London S.E.

Equities

CH0010532478

Press Releases

Unlock all the news: Be the first to know and act before the market!

Actelion : Pharmaceuticals US, Inc, - Results from Expert Delphi Consensus Survey on Treatment of Pulmonary Arterial Hypertension with Oral Prostacyclin Pathway Agents	06/20/06	AQ
Actelion : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017	31/17/31	GL
Actelion : Befreiung von Publizitätspflichten zur Aufrechterhaltung der Kotierung	30/17/30	GL
Actelion : Johnson & Johnson Completes Acquisition of Actelion	16/17/16	GL
Actelion : Publication of Idorsia's prospectus relating to the listing of Idorsia Ltd on SIX Swiss Exchange	16/17/16	PU
Actelion : announces changes to its executive team upon completion of the transaction with Johnson & Johnson	14/17/14	GL
Actelion : Publication of Idorsia's prospectus relating to the listing of Idorsia Ltd on SIX Swiss Exchange	09/17/09	GL
Actelion : Johnson & Johnson announces expected settlement of Actelion tender offer on June 16, 2017	09/17/09	GL
Actelion : provides an update on the Phase III IMPACT program with cadazolid in CDAD	08/17/08	GL
Actelion : provides an update on the progress towards launching Idorsia - Key results for pipeline assets to be developed by Idorsia	22/17/22	GL
Actelion : announces changes to its executive team upon completion of the transaction with Johnson & Johnson	15/17/15	GL
Actelion : Publication of the definitive notice of the end result of Actelion tender offer	27/17/27	GL
Actelion : Publication of the provisional notice of the end result of Actelion tender offer	24/17/24	GL
Actelion : amends its financial reporting schedule	10/17/10	GL
Actelion : Annual General Meeting of Shareholders 2017	05/17/05	GL
Actelion : Johnson & Johnson publishes interim result for Actelion tender offer and declares the tender offer successful	31/17/31	GL
Actelion : issues invitation to 2017 Annual General Meeting of Shareholders	15/17/15	GL
Actelion : is granted marketing authorization by the European Commission for Ledaga (chlormethine gel) for the treatment of MF-CTCL	07/17/07	GL
Actelion : obtains "Epoprostenol ACT" label extension for pediatric PAH patients in Japan	02/17/02	GL
Actelion : Johnson & Johnson publishes prospectus for Actelion tender offer	16/17/16	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Actelion London S.E.

Equities

CH0010532478

Press Releases

Filters